Differential Target Multiplexed™ SCS
endurance therapy Spinal cord stimulation

Differential Target Multiplexed™ SCS endurance therapy is a spinal cord stimulation (SCS) therapy available to treat patients with chronic, intractable pain.

Access clinical posters

DTM™ SCS endurance
therapy overview

Building on the foundation of Differential Target
Multiplexed™ (DTM) spinal cord stimulation (SCS),
DTM™ SCS endurance therapy is an energy modified
multiplexed therapy offering meaningful pain relief,
satisfaction, and quality of life improvements.1 
This enables you to personalize care for those seeking
recharge-free longevity or less frequent recharging.

Inspired by science

DTM™ SCS therapy options are inspired by decades of basic science research and preclinical understanding. In a preclinical study, the DTM™ programming (DTMP) derivatives modulated neuro-inflammatory processes more than low-rate SCS.*2

Clinical results show meaningful pain relief

Study objectives

DTM™ SCS endurance therapy study is a prospective, multicenter, single-arm study designed to evaluate the long-term efficacy and energy use of DTM™ SCS endurance therapy.1

Primary objective: To evaluate the effectiveness of DTM™ SCS endurance therapy in reducing overall pain intensity at 3-months follow up.

Secondary objectives with follow up to 12-months:

  • Characterize changes in pain intensity for overall, back, and leg pain
  • Characterize programming parameters associated with energy use
  • Characterize changes in functional disability as measured by Oswestry disability index (ODI)
  • Characterize subject satisfaction
  • Characterize therapy safety data

12-Month Outcomes

Meaningful
pain relief

4.6

cm reduction in VAS for overall pain
from baseline to 12 months1

Mean overall VAS

Overall pain

Note: *Subjects were excluded from analysis at 6-Months due to programming changes from DTMTM SCS endurance therapy (N=1) and due to study exit (N=1). **Subjects were excluded from analysis at 12-Months due to programming changes from DTMTM SCS endurance therapy (N=2) and due to study exit (N=1)​

Meaningful quality of
life improvements

76%

of patients improved in degree of disability
at 12-month follow up1

Meaning ODI scores

Quality of life graph

Therapy satisfaction

86%

of patients were
satisfied with therapy1

Long lasting

5½-7½

years of recharge-free longevity
estimated using actual
12-month programming data3

Save time

5 minutes

estimated daily rapid recharge
or recharge less frequently
(1 hour every 12 days)3

Superior
pain relief

DTM™ SCS offers proven pain relief backed by data on Intellis™ SCS. Learn about the therapy.

See DTM™ SCS

Vanta™ SCS neurostimulator

High performance and recharge free. Experience DTM™ SCS endurance therapy on Vanta™.
 

Learn more

Intellis™ SCS neurostimulator 

Rapid recharge available with DTM™ SCS or DTM™ SCS endurance therapy. 
 

Discover Intelllis™ SCS

*Note: Data obtained from animal studies should not be extrapolated to clinical/human results.

1

Provenzano, Peacock, Fishman, et al. A prospective multi-center study of a reduced-energy DTM™ stimulation derivative: Long-term outcomes in therapy naïve patients. Poster presented at: American Society of Regional Anesthesia and Pain Medicine (ASRA) Annual Pain Medicine Meeting; Nov. 17–19, 2022; Orlando, FL, USA.

2

Cedeno D, Vallejo R, Platt D, et al. Differential target multiplexed SCS using reduced energy parameters in an animal model of neuropathic pain. Poster presented at: American Society of Pain and Neuroscience (ASPN) annual meeting. July 22&nash;25, 2021.

3

Provenzano, Amirdelfan, Grewal, et al. Modeling energy demands of a reduced-energy derivative of DTM™ stimulation on rechargeable and recharge-free SCS systems. Poster presented at: American Society of Regional Anesthesia and Pain Medicine (ASRA) Annual Pain Medicine Meeting; Nov. 17–19, 2022; Orlando, FL, USA.